Demographics and clinical characteristics of participants who completed the online survey

ParametersQuantitative phase II (n=1050)
Age, years, mean±sd
 At survey60.5±11.0
 At diagnosis53.6±11.3
Time since diagnosis, years, mean±sd7.2±7.0
Age groups %
 40–59 years45
 60–79 years50
 >80 years5
Sex, male %51
Country n (%)
 USA400 (38.1)
 UK200 (19.0)
 France150 (14.3)
 Australia150 (14.3)
 Japan150 (14.3)
Body mass index % (n=954)
 Underweight (<18.5 kg·m−2)4
 Healthy (18.5–24.9 kg·m−2)44
 Overweight (25.0–29.9 kg·m−2)28
 Obese (>30 kg·m−2)24
Smoking status %
 Current smokers29
Comorbidities %
 Gastro-oesophageal reflux disorder22
 Sleep disturbance31
 Urinary incontinence15
 Rheumatology disease15
COPD severity (self-perceived) %
 Severe/very severe35
Severity derived from PRO instruments#, mean±sd
 CAT score25.0±6.67
 CASA-Q score50.3±20.9
Exacerbations in the past 12 months%
Amount of mucus when coughing in the past 7 days %
 A great/very great deal35
 Some/a little62
 None at all3
Asthma/respiratory allergy %
 Since childhood23
 Since adulthood42
 No allergy35
Educational qualification (higher college or university degrees) %
Employment status %
 Currently full time34
 Other (working part time, home maker, on sick leave, student and unemployment)24

PRO: patient-reported outcome; CAT: COPD Assessment Test; CASA-Q: Cough and Sputum Assessment Questionnaire. #: CAT scores range from 0 to 40; higher scores denote a more severe impact of COPD on a patient's life; and CASA-Q domain scores range from 0 to 100, with higher scores associated with fewer symptoms/less impact due to cough or sputum. : that required hospitalisation; higher scores denote a more severe impact of COPD on a patient's life.